Entering text into the input field will update the search result below

Lilly teams up with CureVac to develop cancer vaccines based on mRNA technology

Oct. 18, 2017 7:14 AM ETEli Lilly and Company (LLY) StockBy: Douglas W. House, SA News Editor
  • Eli Lilly (NYSE:LLY) enters into a global immuno-oncology collaboration with Tubingen, Germany-based CureVac AG aimed at developing up to five therapeutic cancer vaccines based on the latter's proprietary RNActive technology which utilizes messenger RNA to target tumor neoantigens for a more robust anticancer immune response.
  • Under the terms of the agreement, CureVac will receive $50M upfront, a €45M equity investment, up to $1.7B in milestones and tiered royalties on net sales. It will be responsible for mRNA design, formulation and manufacturing of clinical supply while retaining the option to co-promote the vaccines in Germany.

Recommended For You

More Trending News

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company